Downregulation of N-myc and STAT Interactor Protein Predicts Aggressive Tumor Behavior and Poor Prognosis in Invasive Ductal Carcinoma
| Autor: | Chang Lim Hyun, Kyung Min Lee, Ji Eun Choi, Han Suk Ryu, Ji Hye Moon, Min Sun Jin |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.drug_class Human Protein Atlas Subgroup analysis 03 medical and health sciences 0302 clinical medicine Breast cancer Downregulation and upregulation medicine Tissue microarray business.industry NMI protein human medicine.disease Databases genetic 030104 developmental biology Oncology Estrogen 030220 oncology & carcinogenesis Cancer research Biomarkers tumor Immunohistochemistry Original Article Breast neoplasms business N-Myc |
| Zdroj: | Journal of Breast Cancer |
| ISSN: | 2092-9900 1738-6756 |
| Popis: | Purpose We investigated the expression of the N-myc and STAT interactor (NMI) protein in invasive ductal carcinoma tissue and estimated its clinicopathologic significance as a prognostic factor. The expression levels and prognostic significance of NMI were also analyzed according to the molecular subgroup of breast cancers. Methods Human NMI detection by immunohistochemistry was performed using tissue microarrays of 382 invasive ductal carcinomas. The correlation of NMI expression with patient clinicopathological parameters and prognostic significance was analyzed and further assessed according to the molecular subgroup of breast cancers. Moreover, in vitro experiments with 13 breast cancer cell lines were carried out. We also validated NMI expression significance in The Cancer Genome Atlas cohort using the Human Protein Atlas (HPA) database. Results Low NMI expression was observed in 190 cases (49.7%). Low NMI expression was significantly associated with the “triple-negative” molecular subtype (p < 0.001), high nuclear grade (p < 0.001), high histologic grade (p < 0.001), and advanced anatomic stage (p = 0.041). Patients with low NMI expression had poorer progression-free survival (p = 0.038) than patients with high NMI expression. Low NMI expression was not significantly associated with patient prognosis in the molecular subgroup analysis. In vitro, a reduction of NMI expression was observed in 8 breast cancer cell lines, especially in the estrogen receptor-positive and basal B type of triple-negative breast cancer molecular subgroups. The HPA database showed that low NMI expression levels were associated with a lower survival probability compared with that associated with high NMI expression (p = 0.053). Conclusion NMI expression could be a useful prognostic biomarker and a potential novel therapeutic target in invasive ductal carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|